LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Elenco Azioni・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Aperta

28.49 -1.15

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.86

Massimo

29.12

Metriche Chiave
By Trading Economics
Entrata	43M 13M
Vendite	29M 107M
EPS	0.25
Margine di Profitto	12.139
Dipendenti	524
EBITDA	16M 8.2M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+128.37% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	17M 1.5B
Apertura precedente	29.64
Chiusura precedente	28.49

Immunocore Holdings PLC ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

28 mag 2026, 22:47 UTC

Utili

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mag 2026, 20:45 UTC

Utili

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mag 2026, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mag 2026, 23:31 UTC

Discorsi di Mercato

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mag 2026, 23:17 UTC

Discorsi di Mercato

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mag 2026, 23:02 UTC

Discorsi di Mercato

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mag 2026, 22:41 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

28 mag 2026, 22:41 UTC

Discorsi di Mercato

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mag 2026, 22:37 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mag 2026, 22:04 UTC

Acquisizioni, Fusioni, Takeovers

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mag 2026, 22:04 UTC

Acquisizioni, Fusioni, Takeovers

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mag 2026, 21:12 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mag 2026, 21:00 UTC

Utili

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mag 2026, 20:57 UTC

Utili

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mag 2026, 20:55 UTC

Utili

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

28 mag 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

28 mag 2026, 20:48 UTC

Azioni calde

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mag 2026, 20:34 UTC

Utili

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mag 2026, 20:31 UTC

Utili

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mag 2026, 20:28 UTC

Utili

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mag 2026, 20:26 UTC

Utili

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mag 2026, 20:20 UTC

Utili

Costco 3Q Membership Fees $1.37B

28 mag 2026, 20:20 UTC

Utili

Costco 3Q Net Sales $69.15B

28 mag 2026, 20:19 UTC

Utili

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mag 2026, 20:19 UTC

Utili

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mag 2026, 20:17 UTC

Utili

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mag 2026, 20:17 UTC

Utili

Costco 3Q Same-Store Sales Up 9.8% >COST

Confronto tra pari

Modifica del prezzo

Immunocore Holdings PLC ADR Previsione

Obiettivo di Prezzo

By TipRanks

128.37% in crescita

Previsioni per 12 mesi

Media 65.13 USD 128.37%

Alto 100 USD

Basso 33 USD

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

9 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 9 che hanno fornito valutazioni azionarie a Immunocore Holdings PLC ADR - Dist negli ultimi 3 mesi.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.